EMA Withdrawn: Rasitrio (aliskiren;amlodipine;hydrochlorothiazide) — Novartis Europharm Ltd.

View source ↗

Summary

EMA has withdrawn Rasitrio (aliskiren; amlodipine; hydrochlorothiazide) from the market for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Rasitrio

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Novartis Europharm Ltd.. Decision date: 03/10/2013